Japanese

Bone and Calcium Abnormalities in Malignancy. Treatment of malignancy associated hypercalcemia. Tai Nobuyuki 1 , Inoue Daisuke 2 1Third Department of Medicine, Teikyo University Chiba Medical Center, Japan. 2Third Department of Medicine, Teikyo University Chiba Medical Center, Japan. pp.1223-1228
Published Date 2014/7/28
DOI https://doi.org/10.20837/4201408099
  • Abstract
  • Look Inside
  • Reference

 Malignancy associated hypercalcemia(MAH)is a paraneoplastic syndrome that impairs the quality of life and that can be a direct cause of death. MAH is classified into two major categories:humoral hypercalcemia of malignancy(HHM)and local osteolytic hypercalcemia(LOH).Bisphosphonates are the gold standard of treatment for MAH, because enhanced resorption causing a massive calcium mobilization from bone plays a central role in the pathogenesis of MAH. Calcitonin can be used initially as an adjunctive therapy, because it takes a few days for bisphosphonates to be effective. Saline infusion is also necessary to improve dehydration and renal insufficiency inevitably accompanying MAH.



基本情報

電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社

関連文献

もっと見る

文献を共有